Shareholders might have noticed that Isoray, Inc. (NYSEMKT:ISR) filed its first-quarter result this time last week. The early response was not positive, with shares down 6.4% to US$0.37 in the past ...

Anyone researching IsoRay, Inc. (NYSEMKT:ISR) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors ...

Investors might want to bet on IsoRay (ISR), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

It is a pleasure to report that the IsoRay, Inc. (NYSEMKT:ISR) is up 91% in the last quarter. But that doesn't change the fact that the returns over the last half decade have been disappointing.

RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing ...

RICHLAND, Wash., May 12, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that the Centers for Medicare and Medicaid Services (CMS) has approved 64 ICD-10-PCS billing codes ...

RICHLAND, Wash., Jan. 08, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of ...

RICHLAND, Wash., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding ...

RICHLAND, Wash. & CORALVILLE, Iowa--(BUSINESS WIRE)--Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, and Viewpoint Molecular Targeting, Inc., a ...

Shareholders might have noticed that Isoray, Inc. (NYSEMKT:ISR) filed its first-quarter result this time last week. The early response was not positive, with shares down 6.4% to US$0.37 in the past ...